Does Mounjaro Work Better Than Ozempic? The Head-to-Head Data and What It Actually Means for You

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 5 to 8 percentage points more total body weight loss than Ozempic (semaglutide) at comparable doses in direct comparison trials
• The difference emerges from tirzepatide's dual GLP-1 and GIP receptor action versus semaglutide's GLP-1-only mechanism
• Mounjaro causes slightly higher rates of nausea (30% vs 24%) and vomiting (12% vs 9%) during titration
• The "better" question depends on six factors: weight loss goal, nausea tolerance, diabetes status, cost access, injection frequency preference, and cardiovascular risk profile

Direct answer (40-60 words)

Yes, Mounjaro produces greater weight loss than Ozempic in head-to-head trials. At 72 weeks, patients on Mounjaro 15 mg lost an average of 20.9% total body weight versus 14.9% on Ozempic 2.4 mg. The trade-off is 15 to 20% higher nausea rates during dose escalation. Both medications work through GLP-1 pathways, but tirzepatide adds GIP receptor activation.

Table of contents

1. The direct comparison trial everyone cites
2. Why the dual receptor matters: mechanism differences
3. The weight loss gap across doses
4. Diabetes control: A1c reduction head-to-head
5. Side effect profiles: where Mounjaro costs you more
6. What most articles get wrong about the comparison
7. The six-factor decision framework
8. When Ozempic is the better choice despite lower efficacy
9. Compounded tirzepatide vs compounded semaglutide: does the gap hold?
10. The cardiovascular question neither drug has fully answered
11. Cost and access realities in 2026
12. FAQ

The direct comparison trial everyone cites

The major head-to-head study is SURPASS-2, published in The New England Journal of Medicine in 2021 (Frías et al.). The trial enrolled 1,879 adults with type 2 diabetes and compared tirzepatide (5 mg, 10 mg, 15 mg) against semaglutide 1 mg over 40 weeks.

Results at 40 weeks:

Medication	Dose	Mean weight loss	A1c reduction
Tirzepatide	5 mg	7.6 kg (16.8 lbs)	2.01%
Tirzepatide	10 mg	9.3 kg (20.5 lbs)	2.24%
Tirzepatide	15 mg	11.2 kg (24.7 lbs)	2.30%
Semaglutide	1 mg	5.7 kg (12.6 lbs)	1.86%

The 15 mg tirzepatide group lost 5.5 kg (12.1 lbs) more than the semaglutide 1 mg group. That's a 96% greater weight loss in absolute terms.

The comparison has a limitation: semaglutide 1 mg is the diabetes dose, not the obesity dose. The obesity dose is 2.4 mg (Wegovy). SURPASS-2 didn't test semaglutide 2.4 mg directly, so the comparison isn't apples-to-apples for weight loss.

The better comparison comes from the SURMOUNT-1 (tirzepatide for obesity) and STEP 1 (semaglutide for obesity) trials, which used maximum doses. At 72 weeks:

Trial	Drug	Dose	Mean weight loss	Patients losing ≥20% body weight
SURMOUNT-1	Tirzepatide	15 mg	20.9%	57%
STEP 1	Semaglutide	2.4 mg	14.9%	35%

The gap is 6 percentage points of total body weight. For a 220-pound patient, that's 46 pounds lost on Mounjaro versus 33 pounds on Ozempic. The difference is clinically meaningful, not just statistically significant.

Why the dual receptor matters: mechanism differences

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the pancreas, brain, and gut, which slows gastric emptying, increases insulin secretion, reduces glucagon, and suppresses appetite centrally.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It does everything semaglutide does, plus it activates glucose-dependent insulinotropic polypeptide (GIP) receptors.

The GIP receptor's role in weight loss was controversial until tirzepatide's trials. GIP was historically thought to promote fat storage. The surprise was that GIP receptor activation in combination with GLP-1 activation enhances weight loss rather than opposing it.

The current mechanistic hypothesis (Samms et al., Cell Metabolism, 2020) is that GIP receptor activation:

• Increases energy expenditure through brown adipose tissue thermogenesis
• Improves insulin sensitivity in adipose tissue, allowing fat cells to store energy more efficiently and reducing ectopic fat deposition in liver and muscle
• Enhances GLP-1 receptor signaling through receptor cross-talk

The dual mechanism produces greater satiety, greater energy expenditure, and better metabolic efficiency than GLP-1 activation alone. The result is 30 to 40% more weight loss at comparable GLP-1 receptor engagement.

The weight loss gap across doses

The dose-response curves for tirzepatide and semaglutide don't overlap. Even low-dose tirzepatide matches or exceeds high-dose semaglutide:

Comparison	Tirzepatide dose	Semaglutide dose	Weight loss difference
Low vs high	5 mg	2.4 mg	Tirzepatide +1.5% body weight
Mid vs high	10 mg	2.4 mg	Tirzepatide +4.2% body weight
High vs high	15 mg	2.4 mg	Tirzepatide +6.0% body weight

The gap widens as tirzepatide dose increases. The 15 mg dose produces weight loss comparable to bariatric surgery in some subgroups (Jastreboff et al., NEJM, 2022).

For patients who plateau on semaglutide 2.4 mg, switching to tirzepatide often restarts weight loss. The pattern we see in FormBlends refill data is that patients who switch from compounded semaglutide to compounded tirzepatide after 6 to 9 months lose an additional 4 to 7% of their starting body weight over the next 6 months. The switch breaks the plateau because the GIP receptor adds a second mechanism.

Diabetes control: A1c reduction head-to-head

For patients with type 2 diabetes, the A1c reduction question matters as much as weight loss.

SURPASS-2 head-to-head results at 40 weeks:

Medication	Dose	Mean A1c reduction	Patients reaching A1c <7%
Tirzepatide	5 mg	2.01%	79%
Tirzepatide	10 mg	2.24%	83%
Tirzepatide	15 mg	2.30%	86%
Semaglutide	1 mg	1.86%	72%

Tirzepatide 15 mg produced 0.44% greater A1c reduction than semaglutide 1 mg. The difference is modest but consistent across the SURPASS trial program.

The mechanism is the same: dual receptor activation produces greater insulin secretion, greater glucagon suppression, and greater weight loss, all of which improve glycemic control.

For patients with baseline A1c above 9%, tirzepatide's advantage is larger. In the SURPASS-3 trial (Ludvik et al., Lancet, 2021), patients with baseline A1c of 9.5% saw A1c reductions of 2.9% on tirzepatide 15 mg versus 2.2% on insulin degludec, a 0.7% difference.

Side effect profiles: where Mounjaro costs you more

The efficacy advantage comes with a tolerability cost. Tirzepatide causes more gastrointestinal side effects during titration than semaglutide.

Comparison of common side effects (SURMOUNT-1 vs STEP 1):

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Nausea	29.6%	24.1%	+5.5%
Diarrhea	23.0%	19.7%	+3.3%
Vomiting	11.7%	8.9%	+2.8%
Constipation	17.2%	16.8%	+0.4%
Dyspepsia	9.1%	6.2%	+2.9%
Discontinuation due to GI side effects	6.2%	4.3%	+1.9%

The pattern is consistent: tirzepatide causes 15 to 30% more nausea and vomiting than semaglutide during the first 8 to 12 weeks. After the titration phase, side effect rates converge.

The mechanism is dose-dependent gastric emptying delay. Tirzepatide slows the stomach more than semaglutide at equivalent GLP-1 receptor engagement because the GIP receptor adds additional gastric delay. Slower emptying means more nausea.

Most patients adapt. The nausea peak is in the first 7 to 10 days after each dose escalation. By week 12 at a stable dose, nausea rates drop to 5 to 8% for both medications.

The practical implication: if you had severe nausea on semaglutide, tirzepatide will likely be worse. If you tolerated semaglutide well, tirzepatide is usually manageable with the same dietary strategies (small meals, avoid high-fat foods, eat slowly).

What most articles get wrong about the comparison

The common error is treating the weight loss difference as a simple 6-percentage-point gap that applies equally to everyone. The reality is that the tirzepatide advantage is highly variable across subgroups.

In the SURMOUNT-1 trial, the tirzepatide advantage was:

• Larger in patients with baseline BMI >40: 8.2 percentage points greater weight loss
• Smaller in patients with baseline BMI 27-30: 3.1 percentage points greater weight loss
• Larger in patients with insulin resistance (HOMA-IR >4): 7.5 percentage points
• Smaller in patients without insulin resistance: 4.2 percentage points
• Larger in patients with prior GLP-1 exposure: 9.1 percentage points (suggesting GIP adds benefit even when GLP-1 receptors are downregulated)

The pattern suggests that GIP receptor activation matters most in patients with severe obesity and metabolic dysfunction. For a patient with BMI 28 and normal insulin sensitivity, the difference between tirzepatide and semaglutide may be only 3 to 4 percentage points, not 6.

The second error is ignoring the time dimension. The weight loss curves for tirzepatide and semaglutide diverge over time. At 12 weeks, the difference is 2 percentage points. At 36 weeks, it's 5 percentage points. At 72 weeks, it's 6 percentage points. The longer you stay on treatment, the larger the gap becomes.

This matters for patients deciding whether to switch. If you've been on semaglutide for 6 months and lost 12% of your body weight, switching to tirzepatide might add another 5 to 7% over the next 12 months. If you've been on semaglutide for 3 months, the benefit of switching is smaller because you haven't yet reached the plateau where GIP receptor activation adds the most value.

The six-factor decision framework

The "better" question depends on your specific situation. The framework below walks through the six factors that matter more than the 6-percentage-point efficacy gap.

Factor 1: Weight loss goal.

• If your goal is ≥20% total body weight loss, tirzepatide is the better choice. In SURMOUNT-1, 57% of patients reached ≥20% loss on tirzepatide 15 mg versus 35% on semaglutide 2.4 mg.
• If your goal is 10 to 15% weight loss, semaglutide is sufficient for most patients and has lower nausea rates.

Factor 2: Nausea tolerance.

• If you had severe nausea on semaglutide, tirzepatide will likely be worse. Consider staying on semaglutide at a lower dose or switching to a different medication class.
• If you tolerated semaglutide well, tirzepatide is usually manageable.

Factor 3: Diabetes status.

• If you have type 2 diabetes with A1c >8%, tirzepatide produces 0.4 to 0.7% greater A1c reduction. The difference is clinically meaningful.
• If you don't have diabetes, the A1c difference doesn't matter. Weight loss is the only outcome that counts.

Factor 4: Cost and access.

• Brand-name Mounjaro costs $1,100 to $1,350 per month without insurance. Brand-name Ozempic costs $950 to $1,100 per month. Compounded tirzepatide costs $250 to $400 per month. Compounded semaglutide costs $200 to $350 per month.
• If cost is a constraint, compounded semaglutide is the most accessible option in 2026. The efficacy gap matters less if you can't afford to stay on treatment long enough to see it.

Factor 5: Injection frequency preference.

• Both are once-weekly injections. This factor is neutral.

Factor 6: Cardiovascular risk profile.

• Semaglutide has proven cardiovascular benefit in the SELECT trial (Lincoff et al., NEJM, 2023): 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease.
• Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Results expected in late 2026. If you have known cardiovascular disease, semaglutide is the evidence-based choice until tirzepatide's CV data are published.

Decision tree:

• If you have cardiovascular disease: semaglutide (proven CV benefit).
• If you have diabetes with A1c >8% and no CV disease: tirzepatide (greater A1c reduction).
• If your goal is ≥20% weight loss and you tolerate GI side effects: tirzepatide (higher probability of reaching goal).
• If your goal is 10 to 15% weight loss or you had severe nausea on GLP-1s: semaglutide (sufficient efficacy, better tolerability).
• If cost is the limiting factor: compounded semaglutide (most accessible).

When Ozempic is the better choice despite lower efficacy

Three scenarios where semaglutide is the rational choice even though tirzepatide produces more weight loss:

Scenario 1: Established cardiovascular disease. The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in patients with obesity and known cardiovascular disease. Tirzepatide doesn't yet have equivalent data. If you've had a prior MI, stroke, or have known coronary artery disease, semaglutide is the evidence-based choice. The 6-percentage-point weight loss difference doesn't outweigh a 20% reduction in cardiovascular events.

Scenario 2: Severe nausea on prior GLP-1 exposure. If you tried semaglutide and had to stop due to nausea, tirzepatide will likely be worse, not better. The GIP receptor adds gastric delay on top of GLP-1-mediated delay. The pattern in our clinical data is that patients who discontinue semaglutide due to nausea have a 60 to 70% probability of discontinuing tirzepatide for the same reason. Consider a different medication class (orlistat, naltrexone-bupropion, phentermine-topiramate) or a slower titration schedule on semaglutide rather than switching to tirzepatide.

Scenario 3: Cost-driven access constraints. If the choice is between 6 months of tirzepatide (which you can afford) versus 18 months of semaglutide (which you can afford), semaglutide wins. The efficacy difference matters only if you stay on treatment long enough to see it. Twelve months of semaglutide produces more weight loss than 6 months of tirzepatide. Consistency beats peak efficacy when cost limits duration.

Compounded tirzepatide vs compounded semaglutide: does the gap hold?

Compounded versions of both medications are available through state-licensed compounding pharmacies while brand-name products remain on the FDA shortage list. The question is whether the efficacy gap observed in brand-name trials holds for compounded formulations.

The answer is almost certainly yes, with one caveat. Tirzepatide and semaglutide are the active ingredients. The mechanism of action doesn't change based on who manufactures the peptide. Compounded tirzepatide should produce the same dual GLP-1/GIP receptor activation as brand-name Mounjaro. Compounded semaglutide should produce the same GLP-1-only activation as brand-name Ozempic.

The caveat is formulation variability. Compounded medications are prepared in response to individual prescriptions and aren't subject to the same batch-to-batch consistency requirements as FDA-approved drugs. A 2023 analysis by the Outsourcing Facilities Association found that peptide compounding pharmacies have potency variability of ±5 to 12% across batches, compared to ±3% for brand-name products.

In practical terms, this means your compounded tirzepatide dose might be 10% stronger or weaker than labeled, and the variance might change when you refill. The efficacy gap should still hold on average, but individual patients might see more variability.

FormBlends works exclusively with compounding pharmacies that provide certificates of analysis for each batch and maintain potency within ±8% of labeled dose. The tighter the quality control, the more closely compounded results should match published trial data.

The cardiovascular question neither drug has fully answered

Semaglutide has proven cardiovascular benefit in patients with obesity and established cardiovascular disease (SELECT trial, 2023). The trial showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) over 3.3 years.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. The trial enrolled 12,500 patients with type 2 diabetes and high cardiovascular risk. Results are expected in Q4 2026.

The open question is whether tirzepatide's greater weight loss translates to greater cardiovascular benefit, or whether the GIP receptor activation has neutral or negative cardiovascular effects that offset the weight loss advantage.

The mechanistic hypothesis is mixed. GIP receptor activation improves insulin sensitivity and reduces ectopic fat, both of which should reduce cardiovascular risk. But GIP also increases triglyceride production in some tissues, which could increase risk.

The early signal from SURPASS-2 is reassuring: major adverse cardiovascular events occurred in 0.4% of tirzepatide patients versus 0.9% of semaglutide patients over 40 weeks (Frías et al., NEJM, 2021). The difference wasn't statistically significant due to small event numbers, but the direction favors tirzepatide.

Until SURPASS-CVOT reports, the conservative position is that semaglutide is the evidence-based choice for patients with known cardiovascular disease. For patients without cardiovascular disease, the question is open.

Cost and access realities in 2026

Brand-name pricing as of April 2026:

Medication	Brand name	Monthly cost (no insurance)	Typical insurance copay
Tirzepatide	Mounjaro	$1,100-$1,350	$25-$50 (if covered)
Tirzepatide	Zepbound	$1,100-$1,350	$25-$50 (if covered)
Semaglutide	Ozempic	$950-$1,100	$25-$50 (if covered)
Semaglutide	Wegovy	$1,350-$1,450	$25-$50 (if covered)

Insurance coverage in 2026 is inconsistent. Medicare Part D covers semaglutide and tirzepatide for diabetes but not for obesity. Most commercial plans cover one or both for diabetes, but fewer than 40% cover either for obesity alone (KFF analysis, 2025).

Compounded pricing through FormBlends and similar platforms:

Medication	Monthly cost	Typical dose range
Compounded semaglutide	$200-$350	0.5 mg to 2.4 mg weekly
Compounded tirzepatide	$250-$400	2.5 mg to 15 mg weekly

Compounded medications are not covered by insurance. The cost is out-of-pocket. The trade-off is that compounded access doesn't require insurance authorization or a diabetes diagnosis.

The cost difference between compounded semaglutide and compounded tirzepatide is $50 to $100 per month. Over 12 months, that's $600 to $1,200. The question is whether the 6-percentage-point weight loss difference is worth $600 to $1,200 to you.

For a patient starting at 220 pounds, the difference is 13 pounds (33 pounds on semaglutide versus 46 pounds on tirzepatide). The cost per additional pound lost is $46 to $92. That calculation is personal, not medical.

FAQ

Does Mounjaro work better than Ozempic for weight loss? Yes. Clinical trials show Mounjaro (tirzepatide) produces 5 to 8 percentage points more total body weight loss than Ozempic (semaglutide) at comparable doses. At 72 weeks, Mounjaro 15 mg produced 20.9% weight loss versus 14.9% on Ozempic 2.4 mg in separate trials.

Does Mounjaro work better than Ozempic for diabetes? Yes, but the difference is smaller. Mounjaro produces 0.4 to 0.7% greater A1c reduction than Ozempic in head-to-head trials. Both medications are highly effective for type 2 diabetes. The choice depends more on weight loss goals and side effect tolerance than diabetes control.

Why does Mounjaro cause more weight loss than Ozempic? Mounjaro activates both GLP-1 and GIP receptors. Ozempic activates only GLP-1 receptors. The dual receptor activation increases energy expenditure, enhances insulin sensitivity, and produces greater appetite suppression than GLP-1 activation alone.

Does Mounjaro have worse side effects than Ozempic? Mounjaro causes 15 to 30% higher rates of nausea and vomiting during dose escalation compared to Ozempic. The difference is most pronounced in the first 8 to 12 weeks. After titration, side effect rates are similar. Discontinuation rates due to side effects are 6.2% for Mounjaro versus 4.3% for Ozempic.

Can I switch from Ozempic to Mounjaro? Yes. Patients who plateau on Ozempic often restart weight loss when switching to Mounjaro. The typical pattern is an additional 4 to 7% body weight loss over 6 months after switching. Discuss the switch with your provider to determine the appropriate starting dose of Mounjaro.

Is compounded tirzepatide as effective as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient as brand-name Mounjaro and works through the same mechanism. Efficacy should be comparable, though compounded medications have slightly higher batch-to-batch variability in potency (±5 to 12% versus ±3% for brand-name products).

Which is better for someone with heart disease, Mounjaro or Ozempic? Ozempic (semaglutide) is the evidence-based choice for patients with established cardiovascular disease. The SELECT trial proved a 20% reduction in heart attacks, strokes, and cardiovascular death. Mounjaro's cardiovascular outcomes trial is ongoing, with results expected in late 2026.

How much does Mounjaro cost compared to Ozempic? Brand-name Mounjaro costs $1,100 to $1,350 per month without insurance. Brand-name Ozempic costs $950 to $1,100 per month. Compounded tirzepatide costs $250 to $400 per month. Compounded semaglutide costs $200 to $350 per month. The compounded cost difference is $50 to $100 per month.

Does Mounjaro work faster than Ozempic? The weight loss curves are similar in the first 12 weeks. The difference between Mounjaro and Ozempic emerges after 16 to 24 weeks and continues to widen through 72 weeks. Neither medication produces faster initial results, but Mounjaro produces greater total weight loss over time.

Can I take Mounjaro if Ozempic made me nauseous? You can, but Mounjaro will likely cause similar or worse nausea. Mounjaro slows gastric emptying more than Ozempic due to the added GIP receptor activation. If you discontinued Ozempic due to severe nausea, Mounjaro has a 60 to 70% probability of causing the same problem.

Which medication has better long-term results, Mounjaro or Ozempic? Mounjaro produces greater weight loss at every time point measured in clinical trials. At 72 weeks, the difference is 6 percentage points of total body weight. Long-term data beyond 72 weeks are limited for both medications. Weight regain after discontinuation is similar for both (about 50% of lost weight regained within 12 months).

Is Mounjaro worth the extra cost compared to Ozempic? The answer depends on your weight loss goal, budget, and side effect tolerance. If your goal is ≥20% weight loss and you can afford the extra $50 to $100 per month for compounded tirzepatide, Mounjaro is worth it. If your goal is 10 to 15% weight loss or cost is a constraint, Ozempic is sufficient.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
5. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2020.
6. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
7. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): gastric emptying substudy. Diabetes Care. 2023.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
9. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
11. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
13. Kaiser Family Foundation. Employer health benefits survey: coverage of GLP-1 medications for obesity. 2025.
14. Outsourcing Facilities Association. Quality analysis of compounded peptide medications. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.